Table 5.
Treatment Group | Congenital Anomaly Outcome (n) | All Offspring (n) | Proportion With Anomalies (%) | Crude OR | 95% CI | OR* | 95% CI |
---|---|---|---|---|---|---|---|
Females, AAD score† | |||||||
No chemo treatment | 24 | 696 | 3.4 | 1.0 | Referent | 1.0 | Referent |
0 (nonalkylator only) | 18 | 668 | 2.7 | 0.77 | 0.40 to 1.48 | 0.73 | 0.37 to 1.44 |
1 | 10 | 441 | 2.3 | 0.66 | 0.31 to 1.39 | 0.63 | 0.29 to 1.37 |
2 | 13 | 370 | 3.5 | 1.03 | 0.52 to 2.03 | 1.00 | 0.49 to 2.03 |
3 | 13 | 330 | 3.9 | 1.15 | 0.58 to 2.26 | 1.13 | 0.57 to 2.25 |
Ptrend | .68 | .69 | |||||
Males, AAD score† | |||||||
No chemo treatment | 12 | 574 | 2.1 | 1.0 | Referent | 1.0 | Referent |
0 (nonalkylator only) | 8 | 455 | 1.8 | 0.83 | 0.32 to 2.16 | 0.92 | 0.32 to 2.59 |
1 | 10 | 398 | 2.5 | 1.16 | 0.50 to 2.70 | 1.29 | 0.52 to 3.22 |
2 or 3‡ | 4 | 335 | 1.2 | 0.57 | 0.18 to 1.79 | 0.59 | 0.19 to 1.86 |
Ptrend | .55 | .62 |
Abbreviation: OR, odds ratio.
ORs adjusted for calendar year of birth and maternal age (for the female analyses) and for calendar year of birth and paternal age (for the male analyses).
Alkylating agent dose score, see Methods for definition.
Scores 2 and 3 were grouped because of small numbers.